UBS Group
TENX icon

UBS Group’s Tenax Therapeutics TENX Stock Holding History

UBS Group’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.1M Buy
381,419
+380,743
+56,323% +$5.15M ﹤0.01% 3848
2025
Q4 		$8.24K Buy
676
+557
+468% +$4.84K ﹤0.01% 8382
2025
Q3 		$906 Buy
119
+105
+750% +$641 ﹤0.01% 9500
2025
Q2 		$81 Sell
14
-2,879
-100% -$16.6K ﹤0.01% 10017
2025
Q1 		$18.9K Buy
2,893
+2,890
+96,333% +$18.5K ﹤0.01% 8270
2024
Q4 		$18 Sell
3
-685
-100% -$3.32K ﹤0.01% 9781
2024
Q3 		$2.38K Sell
688
-811
-54% -$2.94K ﹤0.01% 8442
2024
Q2 		$4.52K Buy
1,499
+115
+8% +$407 ﹤0.01% 8079
2024
Q1 		$5.87K Buy
+1,384
New +$10.6K ﹤0.01% 7500
2023
Q1 		– Sell
-101
Closed -$17.7K – 10361
2022
Q4 		$17.7K Buy
+101
New +$22.2K ﹤0.01% 7803
2022
Q3 		– Hold
0
– – – 10917
2022
Q2 		– Hold
0
– – – 10937
2022
Q1 		– Sell
-3
Closed -$3.34K – 10888
2021
Q4 		$5K Buy
+3
New +$6.76K ﹤0.01% 9417
2021
Q3 		– Sell
-1
Closed -$2.62K – 10077
2021
Q2 		$2K Hold
1
– – ﹤0.01% 8980
2021
Q1 		$2K Sell
1
-5
-83% -$17.8K ﹤0.01% 8644
2020
Q4 		$17K Buy
+6
New +$11K ﹤0.01% 7063
2020
Q3 		– Hold
0
– – – 8400
2020
Q2 		– Sell
-1
Closed -$1.47K – 8347
2020
Q1 		$1K Buy
+1
New +$1.76K ﹤0.01% 7802
2019
Q4 		– Sell
-6
Closed -$11.7K – 8398
2019
Q3 		$11K Buy
6
+5
+500% +$10.4K ﹤0.01% 7116
2019
Q2 		$2K Sell
1
-3
-75% -$7.26K ﹤0.01% 7634
2019
Q1 		$12K Sell
4
-1
-20% -$2.28K ﹤0.01% 6696
2018
Q4 		$10K Buy
5
+4
+400% +$22K ﹤0.01% 7242
2018
Q3 		$12K Sell
1
-1
-50% -$9.44K ﹤0.01% 7075
2018
Q2 		$19K Buy
2
+1
+100% +$10.1K ﹤0.01% 6740
2018
Q1 		$11K Buy
+1
New +$11.5K ﹤0.01% 6817
2017
Q4 		– Hold
0
– – – 7547
2017
Q3 		– Hold
0
– – – 7158
2017
Q2 		– Hold
0
– – – 6726
2016
Q3 		– Hold
0
– -$9K – 7930
2016
Q2 		– Hold
0
– – – 6848
2016
Q1 		– Hold
0
– – – 8161
2015
Q4 		– Hold
0
– – – 6666
2015
Q3 		– Hold
0
– – – 6973
2015
Q2 		– Hold
0
– – – 7711
2015
Q1 		– Hold
0
– – – 7730
2014
Q4 		– Hold
0
– – – 7748

Other funds holding TENX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

UBS Group's TENX Position: Q1 2026 in Review

UBS Group increased its Tenax Therapeutics (TENX) stake by 56,323% in Q1 2026, buying an estimated $5.15M and bringing the position to 381,419 shares worth $6.1M. The position accounts for ﹤0.01% of the portfolio, ranked #3848.

UBS Group first reported a position in TENX in Q1 2018 and has held it in 22 quarters since. 80 funds tracked by Wall St. Rank hold TENX as of Q1 2026.

  • UBS Group held 381,419 shares of Tenax Therapeutics worth $6.1M as of Q1 2026.
  • UBS Group bought 380,743 Tenax Therapeutics shares in Q1 2026, an estimated $5.15M.
  • Tenax Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3848 holding.
  • UBS Group first reported a position in Tenax Therapeutics in Q1 2018 and has held it in 22 quarters since.
  • 80 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.